Payment overview · 2025
General Payments
$761.83
33 reported records · 20 companies
Healthcare provider profile · identity verified
Donald E Harris, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · COLUMBUS, IN · NPI 1508813858
Verified facts
What the public records show
CMS Open Payments records show Donald E Harris, M.D. received $761.83 in general payments during 2025 across 33 reported records.
ABBVIE INC. accounted for 33.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ubrelvy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $257.79 | 33.8% | 8 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $42.65 | 5.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $41.80 | 5.5% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $39.16 | 5.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.55 | 4.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.63 | 4.3% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $30.74 | 4.0% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.25 | 3.8% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.03 | 3.8% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $27.50 | 3.6% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.53 | 3.4% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $23.88 | 3.1% | 1 | 2025 |
| Noctrix Health, Inc. | Unresolved — no canonical attribution shown | $21.44 | 2.8% | 1 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $21.41 | 2.8% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $20.61 | 2.7% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $18.69 | 2.5% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.10 | 2.2% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.79 | 2.1% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $14.73 | 1.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.55 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $761.83 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $235.11 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $114.41 | 6 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $42.65 | 2 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $41.80 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $39.16 | 2 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $37.55 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $32.63 | 2 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $30.74 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $29.25 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $29.03 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $27.50 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $25.53 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $23.88 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| NIDRA Normalized: nidra |
Device | Noctrix Health, Inc. | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 402 | 97 |
| Levetiracetam | Levetiracetam | 348 | 70 |
| Gabapentin | Gabapentin | 237 | 58 |
| Topiramate | Topiramate | 189 | 46 |
| Clonazepam | Clonazepam | 188 | 26 |
| Primidone | Primidone | 164 | 33 |
| Memantine Hcl | Memantine Hcl | 162 | 42 |
| Divalproex Sodium | Divalproex Sodium | 158 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 141 | 41 |
| Lacosamide | Lacosamide | 137 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 120 | 21 |
| Oxcarbazepine | Oxcarbazepine | 117 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 116 | 26 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 98 | 21 |
| Emgality Pen | Galcanezumab-Gnlm | 93 | 12 |
| Pregabalin | Pregabalin | 85 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 24 |
| Lamotrigine | Lamotrigine | 71 | 15 |
| Carbamazepine | Carbamazepine | 68 | 16 |
| Baclofen | Baclofen | 65 | 20 |
| Phenobarbital | Phenobarbital | 65 | suppressed |
| Zonisamide | Zonisamide | 63 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 53 | suppressed |
| Lorazepam | Lorazepam | 48 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 18 |
| Memantine Hcl Er | Memantine Hcl | 44 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 38 | 13 |
| Nurtec Odt | Rimegepant Sulfate | 33 | suppressed |
| Prednisone | Prednisone | 33 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 33 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | suppressed |
| Rivastigmine | Rivastigmine | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Phenytoin | Phenytoin | 30 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Amantadine | Amantadine Hcl | 24 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 24 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 24 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 22 | suppressed |
| Modafinil | Modafinil | 22 | suppressed |
| Ubrelvy | Ubrogepant | 21 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 19 | suppressed |
| Carisoprodol | Carisoprodol | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Teriflunomide | Teriflunomide | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Clobazam | Clobazam | 15 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 14 | suppressed |
| Betaseron | Interferon Beta-1b | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Glatopa | Glatiramer Acetate | 13 | suppressed |
| Lamictal Xr | Lamotrigine | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 11 | suppressed |
| Oxtellar Xr | Oxcarbazepine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $761.83 · 33 records | ABBVIE INC. | BOTOX, CREXONT, HYQVIA, INGREZZA, KESIMPTA, KISUNLA, Leqembi, NIDRA, NUPLAZID, Nayzilam, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, Radicava, UBRELVY, ULTOMIRIS, UPLIZNA, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VYVGART HYTRULO, XYWAV, ZEPOSIA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ubrelvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error